1
|
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, Botto B, Bolis S, Volpetti S, Zilioli VR, Puccini B, Arcari A, Pavone V, Gaidano G, Corradini P, Tani M, Cavallo F, Milone G, Ghiggi C, Pinto A, Pastore D, Ferreri AJM, Latte G, Patti C, Re F, Benedetti F, Luminari S, Pennese E, Bossi E, Boccomini C, Anastasia A, Bottelli C, Ciccone G, Vitolo U. Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial. Ann Oncol 2024; 35:118-129. [PMID: 37922989 DOI: 10.1016/j.annonc.2023.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2023] [Revised: 09/11/2023] [Accepted: 10/03/2023] [Indexed: 11/07/2023] Open
Abstract
BACKGROUND Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter, randomized, phase III FLAZ12 (NCT01827605) trial compared anti-CD20 radioimmunotherapy (RIT) with ASCT as consolidation after chemoimmunotherapy, both followed by rituximab maintenance. PATIENTS AND METHODS Patients (age 18-65 years) with R/R FL and without significant comorbidities were enrolled and treated with three courses of conventional, investigator-chosen chemoimmunotherapies. Those experiencing at least a partial response were randomized 1 : 1 to ASCT or RIT before CD34+ collection, and all received postconsolidation rituximab maintenance. Progression-free survival (PFS) was the primary endpoint. The target sample size was 210 (105/group). RESULTS Between August 2012 and September 2019, of 164 screened patients, 159 were enrolled [median age 57 (interquartile range 49-62) years, 55% male, 57% stage IV, 20% bulky disease]. The study was closed prematurely because of low accrual. Data were analyzed on 8 June 2023, on an intention-to-treat basis, with a 77-month median follow-up from enrollment. Of the 141 patients (89%), 70 were randomized to ASCT and 71 to RIT. The estimated 3-year PFS in both groups was 62% (hazard ratio 1.11, 95% confidence interval 0.69-1.80, P = 0.6662). The 3-year overall survival also was similar between the two groups. Rates of grade ≥3 hematological toxicity were 94% with ASCT versus 46% with RIT (P < 0.001), and grade ≥3 neutropenia occurred in 94% versus 41%, respectively (P < 0.001). Second cancers occurred in nine patients after ASCT and three after radioimmunotherapy (P = 0.189). CONCLUSIONS Even if prematurely discontinued, our study did not demonstrate the superiority of ASCT versus RIT. ASCT was more toxic and demanding for patients and health services. Both strategies yielded similar, favorable long-term outcomes, suggesting that consolidation programs milder than ASCT require further investigation in R/R FL.
Collapse
Affiliation(s)
- M Ladetto
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
| | - R Tavarozzi
- Department of Translational Medicine, University of Eastern Piedmont, Novara; SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Zanni
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - A Evangelista
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - S Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - A Tucci
- Department of Hematology, Spedali Civili, Brescia
| | - B Botto
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - S Bolis
- SC Ematologia ASST-Monza, Monza
| | - S Volpetti
- Division of Hematology, Clinica Ematologica, Centro Trapianti e Terapie Cellulari Carlo Melzi, DISM, Azienda Ospedaliero Universitaria S. M. Misericordia, Udine
| | - V R Zilioli
- Division of Haematology, ASST Grande Ospedale Metropolitano Niguarda, Milano
| | - B Puccini
- Department of Haematology, University of Florence, Firenze
| | - A Arcari
- Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza
| | - V Pavone
- A. O. C. Panico-U.O.C Ematologia e Trapianto, Tricase, Lecce
| | - G Gaidano
- SCDU di Ematologia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Division of Hematology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara
| | - P Corradini
- Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milano
| | - M Tani
- Hematology Unit, Department of Oncology and Hematology, "Santa Maria delle Croci" Hospital, Ravenna
| | - F Cavallo
- Department of Molecular Biotechnologies and Health Sciences, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - G Milone
- Division of Hematology and Program for Hematopoietic Transplantation, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania
| | - C Ghiggi
- Hematology Division, IRCCS Azienda Ospedaliera Universitaria San Martino, IST Istituto Nazionale per la Ricerca sul Cancro, Genova
| | - A Pinto
- Department of Hematology, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico "Fondazione G Pascale", Naples
| | | | - A J M Ferreri
- Onco-Hematology Department, Fondazione Centro San Raffaele, Milano
| | - G Latte
- Unità di Ematologia e Trapianto di Midollo Osseo, San Francesco Hospital, Nuoro
| | - C Patti
- Divisione di Oncoematologia, Azienda Villa Sofia - Cervello, Palermo
| | - F Re
- Department of Hematology, A.O.U. di Parma, Parma
| | - F Benedetti
- Department of Medicine, Section of Hematology and Bone Marrow Transplant Unit, University of Verona, Verona
| | - S Luminari
- Department of Hematology, IRCCS Reggio Emilia, Reggio Emilia
| | - E Pennese
- Lymphoma Unit, Department of Hematology, Ospedale Spirito Santo, Pescara
| | - E Bossi
- SC Ematologia ASST-Monza, Monza
| | - C Boccomini
- Struttura Complessa Ematologia, AOU Città della salute e della scienza di Torino, Turin
| | - A Anastasia
- Department of Hematology, Spedali Civili, Brescia
| | - C Bottelli
- Department of Hematology, Spedali Civili, Brescia
| | - G Ciccone
- SSD of Clinical Epidemiology, Universitaria Città della Salute e della Scienza di Torino and Centre for Cancer Prevention Piemonte, Torino
| | - U Vitolo
- Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy
| |
Collapse
|
2
|
Pinato D, Aguilar-Company J, Bertuzzi A, Hanbury G, Bower M, Salazar R, Lambertini M, Pedrazzoli P, Lee A, Sinclair A, Townsend S, Plaja Salarich A, Sita-Lumsden A, Mukherjee U, Diamantis N, Sharkey R, Gaidano G, Gennari A, Tabernero J, Cortellini A. 504P SARS-CoV-2 Omicron (B.1.1.529) variant infection leads to high morbidity and mortality in unvaccinated patients with cancer. Ann Oncol 2022. [PMCID: PMC9472535 DOI: 10.1016/j.annonc.2022.07.632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
3
|
Mennitto A, Biello F, Forti L, Siffredi G, Mokhtar Mahmoud A, Invernizzi F, Maggiora P, Rua A, Branni C, Gioffi E, Martini V, Gobbato S, Pisani C, Ferrara E, Cappelli M, Catania E, Ferrante D, Gaidano G, Krengli M, Gennari A. 1596P The G8 screening tool as an independent predictor of survival in elderly cancer patients. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
4
|
Moia R, Favini C, Talotta D, Sagiraju S, Bruna R, Dondolin R, Della Starza I, Soscia R, Andorno A, Mercalli F, Deambrogi C, Rasi S, Petrucci L, Bellissimo T, Luciano Boldorini R, Di Rocco A, Del Giudice I, Martelli M, Foà R, Gaidano G. P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS. Hemasphere 2022. [PMCID: PMC9431283 DOI: 10.1097/01.hs9.0000847988.92666.b7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
5
|
Crisà E, Zallio F, Zacchi G, Cerrano M, Rivolta G, Ferrero D, Deambrogi C, Essa W, Awikeh B, Nicolosi M, Santini V, Gaidano G, Bruno B, Patriarca A. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation - Bridging to transplantation. Leuk Res 2021. [DOI: 10.1016/j.leukres.2021.106680.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Pinato D, Patel M, Lambertini M, Colomba E, Pommeret F, Van Hemelrijick M, Zambelli A, Newsom-Davis T, Salazar R, Bertuzzi A, Gaidano G, Rizzo G, Patel G, Felip E, Prat A, Aguilar-Company J, Tabernero J, Diamantis N, Gennari A, Cortellini A. 1565MO Time-dependent improvement in the clinical outcomes from COVID-19 in cancer patients: An updated analysis of the OnCovid registry. Ann Oncol 2021. [PMCID: PMC8454391 DOI: 10.1016/j.annonc.2021.08.1558] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Conconi A, Chiappella A, Orsucci L, Gaidano G, Ferreri AJ, Balzarotti M, Tucci A, Botto B, Moccia A, Vanazzi A, Merli F, Tani M, Esposito F, Bonomini L, Vitolo U, Zucca E. INTENSIFIED (INTRAVENOUS AND INTRATHECAL) CNS PROPHYLAXIS IN PRIMARY TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: 5‐YEAR RESULTS OF THE IELSG30 TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.48_2879] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Conconi
- Azienda sanitaria locale Biella Ospedale degli Infermi ‐ Ematologia Biella Italy
| | - A. Chiappella
- A.O.U Città della Salute e della Scienza di Torino Dipartimento di Oncologia ed Ematologia Torino Italy
| | - L. Orsucci
- A.O.U Città della Salute e della Scienza di Torino Dipartimento di Oncologia ed Ematologia Torino Italy
| | - G. Gaidano
- Azienda Ospedaliera "Maggiore della Carità" Ematologia Novara Italy
| | - Andrés J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Unità Operativa di Oncologia Medica Milano Italy
| | - M. Balzarotti
- Istituto Clinico Humanitas U.O. Oncologia Medica ed Ematologia Milano Rozzano Italy
| | - A. Tucci
- Spedali Civili, SC Ematologia Brescia Italy
| | - B. Botto
- A.O.U Città della Salute e della Scienza di Torino Dipartimento di Oncologia ed Ematologia Torino Italy
| | - A. Moccia
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - A. Vanazzi
- Istituto Europeo di Oncologia Oncoematologia Milano Italy
| | - F. Merli
- Azienda Ospedaliera di Reggio Emilia Arcispedale Santa Maria Nuova ‐ Ematologia Reggio Emilia Italy
| | - M. Tani
- Ospedale Santa Maria delle Croci Dipartimento di Oncologia ed Ematologia Ravenna Italy
| | - F. Esposito
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - L. Bonomini
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Bellinzona Switzerland
| | - U. Vitolo
- Candiolo Cancer Institute FPO‐IRCCS Oncologia Medica Candiolo Italy
| | - E. Zucca
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| |
Collapse
|
8
|
Condoluci A, Terzi‐di‐Bergamo L, Forestieri G, Moia R, Deambrogi C, Deodato M, Frustaci AM, Merli M, Mattarucchi R, Autore F, Fahrni G, Scarfò L, Gussetti D, Bulian P, Zanatta A, Spina V, Faderl MR, Bruscaggin A, Pini K, Piffaretti D, Koch R, Pirosa MC, Cittone MG, Passweg J, Cavalli F, Zucca E, Gerber B, Gillessen S, Stüssi G, Gattei V, Ghia P, Gregor M, Laurenti L, Passamonti F, Tedeschi A, Gaidano G, Rossi D. IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA. Hematol Oncol 2021. [DOI: 10.1002/hon.45_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Condoluci
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - L. Terzi‐di‐Bergamo
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - G. Forestieri
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - R. Moia
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - C. Deambrogi
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - M. Deodato
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - A. M. Frustaci
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - M. Merli
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - R. Mattarucchi
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - F. Autore
- Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Hearth, Hematology Institute Rome Italy
| | - G. Fahrni
- Cantonal Hospital Lucerne Division of Haematology and Central Haematology Laboratory Lucerne Switzerland
| | - L. Scarfò
- IRCCS San Raffaele Scientific Institute and Vita‐Salute San Raffaele University Strategic Research Program on CLL, Division of Experimental Oncology Milan Italy
| | - D. Gussetti
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - P. Bulian
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - A. Zanatta
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - V. Spina
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - M. R. Faderl
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - A. Bruscaggin
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - K. Pini
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - D. Piffaretti
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - R. Koch
- Institute of Oncology Research Laboratory of Experimental Hematology Bellinzona Switzerland
| | - M. C. Pirosa
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - M. G. Cittone
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - J. Passweg
- University Hospital Basel Department of Haematology Basel Switzerland
| | - F. Cavalli
- Università della Svizzera Italiana Institute of Oncology Research Bellinzona Switzerland
| | - E. Zucca
- Oncology Institute of Southern Switzerland Clinic of Oncology Bellinzona Switzerland
| | - B. Gerber
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - S. Gillessen
- Oncology Institute of Southern Switzerland Clinic of Oncology Bellinzona Switzerland
| | - G. Stüssi
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| | - V. Gattei
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - P. Ghia
- IRCCS San Raffaele Scientific Institute and Vita‐Salute San Raffaele University Strategic Research Program on CLL, Division of Experimental Oncology Milan Italy
| | - M. Gregor
- Cantonal Hospital Lucerne Division of Haematology and Central Haematology Laboratory Lucerne Switzerland
| | - L. Laurenti
- Fondazione Policlinico Universitario A. Gemelli, Catholic University of the Sacred Hearth, Hematology Institute Rome Italy
| | - F. Passamonti
- University of Insubria Ospedale di Circolo e Fondazione Macchi, Department of Hematology Varese Italy
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Niguarda Cancer Center, Department of Hematology Milan Italy
| | - G. Gaidano
- University of Eastern Piedmont Department of Translational Medicine, , Division of Hematology Novara Italy
| | - D. Rossi
- Oncology Institute of Southern Switzerland Clinic of Hematology Bellinzona Switzerland
| |
Collapse
|
9
|
Moia R, Favini C, Ferri V, Terdi Di Bergamo L, Schipani M, Forestieri G, Sagiraju S, Andorno A, Rasi S, Talotta D, Al Essa W, Adhinaveni R, Bruscaggin A, Spina V, Paoli L, Margiotta Casaluci G, Patriarca A, Boldorini RL, Rossi D, Gaidano G. DISSECTING THE GENETICS OF DIFFERENT ANATOMICAL COMPARTMENTS OF SMALL LYMPHOCYTIC LYMPHOMA WITH A MULTIREGIONAL SEQUENCING APPORACH. Hematol Oncol 2021. [DOI: 10.1002/hon.54_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- R. Moia
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - C. Favini
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - V. Ferri
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - L. Terdi Di Bergamo
- Institute of Oncology Research Oncology Institute of Southern Switzerland Bellinzona Switzerland
| | - M. Schipani
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - G. Forestieri
- Institute of Oncology Research Oncology Institute of Southern Switzerland Bellinzona Switzerland
| | - S. Sagiraju
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - A. Andorno
- Università del Piemonte Orientale Department of Pathology Novara Italy
| | - S. Rasi
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - D. Talotta
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - W. Al Essa
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - R. Adhinaveni
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - A. Bruscaggin
- Institute of Oncology Research Oncology Institute of Southern Switzerland Bellinzona Switzerland
| | - V. Spina
- Institute of Oncology Research Oncology Institute of Southern Switzerland Bellinzona Switzerland
| | - L. Paoli
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - G. Margiotta Casaluci
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - A. Patriarca
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - R. L. Boldorini
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| | - D. Rossi
- Institute of Oncology Research Oncology Institute of Southern Switzerland Bellinzona Switzerland
| | - G. Gaidano
- Università del Piemonte Orientale Division of Hematology, Department of Translational Medicine Novara Italy
| |
Collapse
|
10
|
Duell J, Maddocks KJ, González‐Barca E, Jurczak W, Liberati AM, Obr A, Gaidano G, Abrisqueta P, André M, Dreyling M, Menne T, Dirnberger‐Hertweck M, Weirather J, Ambarkhane S, Salles G. LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL). Hematol Oncol 2021. [DOI: 10.1002/hon.28_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- J Duell
- Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik II Würzburg Germany
| | - K. J Maddocks
- Arthur G James Comprehensive Cancer Center Ohio State University Wexner Medical Center Department of Internal Medicine Columbus USA
| | - E González‐Barca
- Institut Catalá d’Oncologia (ICO) Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona Department of Hematology Barcelona Spain
| | - W Jurczak
- Maria Sklodowska‐Curie National Research Institute of Oncology Department of Clinical Oncology Kraków Poland
| | - A. M Liberati
- Azienda Ospedaliera Santa Maria di Terni Università degli Studi di Perugia Terni Italy
| | - A Obr
- Palacký University and University Hospital Olomouc Department of Hemato‐Oncology Olomouc Czech Republic
| | - G Gaidano
- University of Piemonte Orientale Amedeo Avogadro Division of Hematology Department of Translational Medicine Novara Italy
| | - P Abrisqueta
- Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron University Hospital Department of Hematology Barcelona Spain
| | - M André
- Université Catholique de Louvain CHU UCL Namur Department of Haematology Yvoir Belgium
| | - M Dreyling
- University Hospital Ludwig‐Maximilians Munich Germany
| | - T Menne
- Freeman Hospital Newcastle Upon Tyne Hospitals NHS Foundation Trust Department of Haematology Newcastle Upon Tyne UK
| | | | | | - S Ambarkhane
- MorphoSys AG Clinical Development Planegg Germany
| | - G Salles
- Hospices Civils de Lyon and Université de Lyon Hématologie Lyon France
| |
Collapse
|
11
|
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Silva MG, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez‐Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Sabattini E, Salles G, Santambrogio E, Scarfó L, Stathis A, Stüssi G, Geyer JT, Tapia G, Thieblemont C, Tousseyn T, Tucci A, Visco C, Vitolo U, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, Leval L, Dirnhofer S, Pileri SA, Piris MÁ, Traverse‐Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.43_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Ferrero S, Moia R, Cascione L, Zaccaria GM, Rinaldi A, Alessandria B, Grimaldi D, Favini C, Evangelista A, Schipani M, Narni F, Stelitano C, Stefani PM, Benedetti F, Mian M, Casaroli I, Zanni M, Castellino C, Pavone V, Galimberti S, Re F, Rossi D, Cortelazzo S, Gaidano G, Ladetto M, Bertoni F. A COMPLETELY GENETIC PROGNOSTIC MODEL OVERCOMES CLINICAL PROGNOSTICATORS IN MANTLE CELL LYMPHOMA: RESULTS FROM THE MCL0208 TRIAL FROM THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.59_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. Ferrero
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Hematology 1, AOU "Città della salute e della scienza di Torino" Torino Italy
| | - R. Moia
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - L. Cascione
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona SIB Swiss Institute of Bioinformatics Lausanne Switzerland
| | - G. M. Zaccaria
- Hematology and Cell Therapy Unit IRCCS Istituto Tumori 'Giovanni Paolo II' Bari Italy
| | - A. Rinaldi
- Institute of Oncology Research Faculty of Biomedical Sciences USI Bellinzona Switzerland
| | - B. Alessandria
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Torino Italy
| | - D. Grimaldi
- Hematology Department of Molecular Biotechnologies and Health Sciences University of Torino Torino Italy
| | - C. Favini
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - A. Evangelista
- Unit of Cancer Epidemiology CPO Piemonte A.O.U. Città della Salute e della Scienza di Torino Torino Italy
| | - M. Schipani
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - F. Narni
- Department of Medical and Surgical Sciences Section of Hematology University of Modena and Reggio Emilia Azienda Ospedaliero Universitaria Policlinico Modena Italy
| | - C. Stelitano
- Hematology Department AO "Bianchi‐Melacrino‐Morelli" Reggio Calabria Italy
| | - P. M. Stefani
- Hematology Unit General Hospital Ca' Foncello Treviso Italy
| | - F. Benedetti
- Hematology University Division Verona Hospital Verona Italy
| | - M. Mian
- Department of Haematology and CBMT Bolzano Hospital Bolzano Italy
| | - I. Casaroli
- Haematology Unit ASST Monza San Gerardo Monza Italy
| | - M. Zanni
- Hematology Unit Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
| | - C. Castellino
- Department of Hematology S. Croce e Carle Hospital Cuneo Italy
| | - V. Pavone
- UOC Ematologia e Trapianto Az. Osp. C. Panico Tricase Italy
| | - S. Galimberti
- Section of Hematology Department of Clinical and Experimental Medicine University of Pisa Pisa Italy
| | - F. Re
- Haematology and Bone Marrow Transplant Unit Parma General Hospital Parma Italy
| | - D. Rossi
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona, Switzerland Oncology Institute of Southern Switzerland (IOSI) Bellinzona,Bellinzona Switzerland
| | - S. Cortelazzo
- Oncology Unit Italy Medical & Center Hospital Humanitas Gavazzeni and Castelli Bergamo Italy
| | - G. Gaidano
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara Italy
| | - M. Ladetto
- Division of Hematology Department of Translational Medicine Università del Piemonte Orientale Novara, Division of Hematology Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo Alessandria Italy
| | - F. Bertoni
- Institute of Oncology Research Faculty of Biomedical Sciences USI, Bellinzona, Switzerland Oncology Institute of Southern Switzerland (IOSI) Bellinzona,Bellinzona Switzerland
| |
Collapse
|
13
|
Terzi di Bergamo L, Forestieri G, Loh JW, Singh A, Spina V, Zucchetto A, Condoluci A, Faderl M, Koch R, Bruscaggin A, Pini K, Wu W, Piffaretti D, Bittolo T, Tissino E, Paoli L, Deambrogi C, Frustaci AM, Autore F, Merli M, Scarfò L, Rasi S, Passweg J, Moia R, Martines C, Ghia P, Cavalli F, Zucca E, Gerber B, Gillessen S, Stüssi G, Montillo M, Passamonti F, Gregor M, Laurenti L, Tedeschi A, Gaidano G, Efremov D, Gattei V, Khiabanian H, Rossi D. ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAY. Hematol Oncol 2021. [DOI: 10.1002/hon.29_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
14
|
Kurtz DM, Chabon JJ, Soo J, Co Ting Keh L, Alig S, Schultz A, Jin MC, Scherer F, Craig AFM, Liu CL, Dührsen U, Hüttmann A, Casasnovas R, Westin JR, Roschewski M, Wilson WH, Gaidano G, Rossi D, Diehn M, Alizadeh AA. PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETECTION AT THE END OF THERAPY. Hematol Oncol 2021. [DOI: 10.1002/hon.25_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- D. M Kurtz
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - J. J Chabon
- Foresight Diagnostics Research and Development Aurora Colorado USA
| | - J Soo
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - L Co Ting Keh
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - S Alig
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - A Schultz
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - M. C Jin
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - F Scherer
- Freiburg University Medical Center Hematology Freiburg Germany
| | - A. F. M Craig
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - C. L Liu
- Stanford University, Medicine Division of Oncology Stanford California USA
| | - U Dührsen
- University Hospital Essen Hematology Essen Germany
| | - A Hüttmann
- University Hospital Essen Hematology Essen Germany
| | - R.‐O Casasnovas
- Hopital F. Mitterrand CHU. Dijon and INSERM 1231 Hematology Dijon France
| | - J. R Westin
- MD Anderson Cancer Center Department of Lymphoma/Myeloma Houston Texas USA
| | - M Roschewski
- National Cancer Institute Lymphoid Malignancies Branch Bethesda Maryland USA
| | - W. H Wilson
- National Cancer Institute Lymphoid Malignancies Branch Bethesda Maryland USA
| | - G Gaidano
- University of Eastern Piedmont Division of Hematology, Department of Translational Medicine Novara Italy
| | - D Rossi
- Oncology Institute of Southern Switzerland and Institute of Oncology Research Hematology Bellinzona Switzerland
| | - M Diehn
- Stanford University Radiation Oncology Stanford California USA
| | - A. A Alizadeh
- Stanford University, Medicine Division of Oncology Stanford California USA
| |
Collapse
|
15
|
Frustaci AM, Tedeschi A, Zinzani PL, Pietrasanta D, Coscia M, Zenz T, Motta M, Gaidano G, Scarfò L, Deodato M, Zamprogna G, Vitale C, Cairoli R, Rossi D, Montillo M. MOLTO, A MULTICENTER, OPEN LABEL, UNCONTROLLED, PHASE II CLINICAL TRIAL ON VENETOCLAX, ATEZOLIZUMAB, OBINUTUZUMAB IN RICHTER TRANSFORMATION: SAFETY INTERIM ANALYSIS. Hematol Oncol 2021. [DOI: 10.1002/hon.40_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. M. Frustaci
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - A. Tedeschi
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - P. L. Zinzani
- "L. e A. Seràgnoli," University of Bologna Hematology Bologna Italy
| | - D. Pietrasanta
- Azienda Ospedaliera SS Arrigo e Biagio e Cesare Arrigo Hematology Alessandria Italy
| | - M. Coscia
- A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Hematology Torino Italy
| | - T. Zenz
- University Hospital Zürich and University of Zürich Hematology Zurich Switzerland
| | - M. Motta
- ASST Spedali Civili Hematology Brescia Italy
| | - G. Gaidano
- University of Eastern Piedmont Translational Medicine, Division of Hematology Novara Italy
| | - L. Scarfò
- Università Vita‐Salute San Raffaele and IRCC Ospedale San Raffaele Hematology Milano Italy
| | - M. Deodato
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - G. Zamprogna
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - C. Vitale
- A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences University of Torino Hematology Torino Italy
| | - R. Cairoli
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| | - D. Rossi
- Oncology Institute of Southern Switzerland; Institute of Oncology Research Hematology Bellinzona Switzerland
| | - M. Montillo
- ASST Grande Ospedale Metropolitano Niguarda Hematology Milan Italy
| |
Collapse
|
16
|
Spina V, Pirosa MC, Bruscaggin A, Condoluci A, Pini K, Forestieri G, Zangrilli I, di Trani M, Kurlapski M, Moccia A, Moia R, Bulian P, Annunziata S, Borsatti E, Rodari M, Romanowicz G, Sacchetti GM, Faderl M, Koch R, Piffaretti D, Terzi di Bergamo L, Stasia A, Cittone M, Chauvie S, Stüssi G, Gerber B, Stathis A, Sommer SG, Cavalli F, Zucca E, Gattei V, Zaucha JM, Pinto A, Gaidano G, Carlo‐Stella C, Hohaus S, Ceriani L, Rossi D. CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.70_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Conconi A, Vannata B, Janikova A, Ramirez A, Bodoni CL, Nowakowski G, Mian M, Ferreri AJ, Ryan G, Pangalis GA, Cabrera ME, Luminari S, Montoto S, Tsang R, Aurer I, Visco C, Mazzucchelli L, Trneny M, Gaidano G, Federico M, Lopez‐Guillermo A, Pro B, Zucca E. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31). Hematol Oncol 2021. [DOI: 10.1002/hon.78_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Conconi
- Azienda sanitaria locale Biella Ospedale degli Infermi ‐ Ematologia Biella Italy
| | - B. Vannata
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - A. Janikova
- University Hospital Brno Department of Hematology and Oncology Brno Czech Republic
| | - A. Ramirez
- Instituto Nacional de Cancerologia Hematology Department Mexico City Mexico
| | - C. Lobetti Bodoni
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - G. Nowakowski
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - M. Mian
- Ospedale di Bolzano Ematologia e Centro Trapianto Midollo Osseo Bolzano Italy
| | - Andrés J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Unità Operativa di Oncologia Medica Milano Italy
| | - G. Ryan
- Peter MacCallum Cancer Institute Deptment of Radiation Oncology Melbourne Australia
| | - G. A. Pangalis
- Athens Medical Center‐Psychikon Branch Hematology Department Athens Greece
| | - M. E. Cabrera
- Hospital del Salvador Facultad de Medicina Santiago Chile
| | - S. Luminari
- Arcispedale Santa Maria Nuova Servizio di Ematologia Reggio Emilia Italy
| | - S. Montoto
- St. Bartholomew’s Hospital Department of Medical Oncology London UK
| | - R. Tsang
- University Health Network Princess Margaret Hospital Toronto Canada
| | - I. Aurer
- University Hospital Centre Zagreb Division of Hematology Zagreb Croatia
| | - C. Visco
- University of Verona Departmento of Medicine ‐ Section of Hematology Verona Italy
| | | | - M. Trneny
- Charles University General Hospital Prague First Faculty of Medicine Prague Czech Republic
| | - G. Gaidano
- Azienda Ospedaliera "Maggiore della Carità" Ematologia Novara Italy
| | - M. Federico
- Università degli Studi di Modena e Reggio Emilia Centro Oncologico Modenese Modena Italy
| | | | - B. Pro
- Northwestern Medicine Hematology and Medical Oncology Chicago Illinois USA
| | - E. Zucca
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| |
Collapse
|
18
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
19
|
Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol 2019; 29:1266-1272. [PMID: 29444231 PMCID: PMC5961010 DOI: 10.1093/annonc/mdy056] [Citation(s) in RCA: 92] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Background This two-stage, phase IIa study investigated the antitumor activity and safety of MOR208, an Fc-engineered, humanized, CD19 antibody, in patients with relapsed or refractory (R-R) B-cell non-Hodgkin’s lymphoma (NHL). CD19 is broadly expressed across the B-lymphocyte lineage, including in B-cell malignancies, but not by hematological stem cells. Patients and methods Patients aged ≥18 years, with R-R NHL progressing after ≥1 prior rituximab-containing regimen were enrolled into subtype-specific cohorts: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), other indolent (i)NHL and mantle cell lymphoma (MCL). Treatment was MOR208, 12 mg/kg intravenously, weekly, for 8 weeks. Patients with at least stable disease could continue treatment for an additional 4 weeks. Those with a partial or complete response after 12 weeks could receive extended MOR208 treatment (12 mg/kg, either monthly or every second week) until progression. The primary end point was overall response rate. Results Ninety-two patients were enrolled: DLBCL (n = 35), FL (n = 34), other iNHL (n = 11) and MCL (n = 12). Responses were observed in DLBCL, FL and other iNHL cohorts (26%, 29% and 27%, respectively). They lasted ≥12 months in 5/9 responding patients with DLBCL, 4/9 with FL and 2/3 with other iNHL. Responses in nine patients are ongoing (>26 months in five instances). Patients with rituximab refractory disease showed a similar response rate and progression-free survival time to patients with non-refractory disease. The most common adverse events (any grade) were infusion-related reactions (12%) and neutropenia (12%). One patient experienced a grade 4 infusion-related reaction and eight patients (9%) experienced grade 3/4 neutropenia. No treatment-related deaths were reported. Conclusions MOR208 monotherapy demonstrated promising clinical activity in patients with R-R DLBCL and R-R FL, including in patients with rituximab refractory tumors. These efficacy data and the favorable safety profile support further investigation of MOR208 in phase II/III combination therapy trials in R-R DLBCL. ClinicalTrials.gov number NCT01685008.
Collapse
Affiliation(s)
- W Jurczak
- Department of Hematology, Jagiellonian University, Kraków, Poland.
| | - P L Zinzani
- Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, USA
| | - M Provencio
- Department of Medical Oncology, University Hospital Puerta De Hierro, Madrid, Spain
| | - Z Nagy
- First Department of Internal Medicine, Semmelweis University, Budapest, Hungary
| | - T Robak
- Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
| | - K Maddocks
- Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| | - C Buske
- Comprehensive Cancer Center Ulm, Institute of Experimental Cancer Research, University Hospital of Ulm, Ulm
| | | | | | | | | | - K A Blum
- Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
| |
Collapse
|
20
|
Salles G, Duell J, González Barca E, Jurczak W, Liberati A, Nagy Z, Obr A, Gaidano G, Andre M, Kalakonda N, Dreyling M, Zinzani P, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Maddocks K. PRIMARY ANALYSIS RESULTS OF THE SINGLE-ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (L-MIND). Hematol Oncol 2019. [DOI: 10.1002/hon.130_2629] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. Salles
- Hospices Civils de Lyon; Centre Hospitalier Lyon Sud, Service d'Hématologie; Pierre-Bénite France
| | - J. Duell
- Medizinische Klinik und Poliklinik II; University Hospital of Würzburg; Würzburg Germany
| | - E. González Barca
- Department of Hematology; Institut Catalá d'Oncología, Hospital Duran i Reynals, IDIBELL; Barcelona Spain
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Kraków Poland
| | - A.M. Liberati
- SC Oncoematologia; Azienda Ospedaliera Santa Maria; Terni Italy
| | - Z. Nagy
- First Department of Internal Medicine; Semmelweis University; Budapest Hungary
| | - A. Obr
- Department of Hemato-Oncology; Palacký University Olomouc and the University Hospital Olomouc; Olomouc Czech Republic
| | - G. Gaidano
- Division of Haematology; Department of Translational Medicine, University of Eastern Piedmont; Novara Italy
| | - M. Andre
- Department of Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - N. Kalakonda
- Department of Haemato-oncology; Clatterbridge Cancer Centre and University of Liverpool; Wirral United Kingdom
| | - M. Dreyling
- Department of Medicine III; University Hospital of Ludwig-Maximilians-Universität; Munich Germany
| | - P.L. Zinzani
- Institute of Hematology “L. e A. Seràgnoli”; University of Bologna; Bologna Italy
| | | | - J. Weirather
- Department of Biostatistics and Data Management; MorphoSys AG; Planneg Germany
| | - S. Ambarkhane
- Department of Clinical Development; MorphoSys AG; Planegg Germany
| | - K. Maddocks
- Department of Internal Medicine; Division of Hematology, The Ohio State University Comprehensive Cancer Center; Columbus Ohio United States
| |
Collapse
|
21
|
Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foà R, Falini B. THE BRAF INHIBITOR VEMURAFENIB PLUS RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE RESPONSES IN RELAPSED/REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL. Hematol Oncol 2019. [DOI: 10.1002/hon.72_2629] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. Tiacci
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - L. De Carolis
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - E. Simonetti
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - F. Zaja
- Hematology Unit; Azienda Sanitaria Universitaria Integrata-Ospedale Maggiore; Trieste Italy
| | - M. Capponi
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| | - A. Ambrosetti
- Department of Medicine; Section of Hematology; Verona Italy
| | - E. Lucia
- Hematology Unit; Ospedale di Cosenza; Cosenza Italy
| | - A. Antolino
- Hematology Unit, Department of Transfusional Medicine - SIMMT; Maria Paternò-Arezzo Hospital; Ragusa Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - S. Ferrari
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - P. Zinzani
- Institute of Hematology, Policlinico Sant'Orsola-Malpighi; University of Bologna; Bologna Italy
| | - L. Rigacci
- Hematology and Stem Cell Transplant Unit; AO San Camillo Forlanini; Roma Italy
| | - G. Gaidano
- Department of Translational Medicine, Division of Hematology; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | | | | | - P. Falcucci
- Hematology Unit; Ospedale di Ronciglione; Viterbo Italy
| | - G. Visani
- Hematology Unit; Ospedale di Pesaro; Pesaro Italy
| | - R. Foà
- Hematology Unit, Department of Translational and Precision Medicine; "Sapienza" University of Rome; Roma Italy
| | - B. Falini
- Institute of Hematology and Center for Hemato-Oncology Research; University and Hospital of Perugia; Perugia Italy
| |
Collapse
|
22
|
Balzarotti M, Ricardi U, Spina M, Monagheddu C, Tucci A, Cavallo F, Zanni M, Arcari A, Rusconi C, Sartori R, Merli F, Re F, Vitolo U, Dessi D, Melis L, Gaidano G, Chiti A, Deidda M, Santoro A, Ciccone G, Chauvie S, Cabras M. PET-DRIVEN RADIOTHERAPY IN PATIENTS WITH LOW RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): THE DLCL10 MULTICENTER PHASE 2 TRIAL BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2019. [DOI: 10.1002/hon.62_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- M. Balzarotti
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - U. Ricardi
- Radiotherapy; AOU Città della Salute e della Scienza, University of Torino; Torino Italy
| | - M. Spina
- Medical Oncology; IRCCS CRO; Aviano (PN) Italy
| | - C. Monagheddu
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - A. Tucci
- Hematology; Spedali Civili; Brescia
| | - F. Cavallo
- Hematology; Universita' Citta' della Salute e della Scienza; Torino Italy
| | - M. Zanni
- Hematology; ASO ss Antonio e Biagio e Arrigo; Alessandria Italy
| | - A. Arcari
- Hematology; Ospedale Guglielmo da Saliceto; Piacenza Italy
| | - C. Rusconi
- Hemtaology; ASST Grande Ospedale Metropolitano Niguarda; Milano Italy
| | - R. Sartori
- Hematology; Azienda ULSS 2 Marca Trevigiana; Castelfranco Veneto Treviso Italy
| | - F. Merli
- Hematology; Arcispedale Santa Maria Nuova; Reggio Emilia Italy
| | - F. Re
- Hematology; AOU Parma; Parma Italy
| | - U. Vitolo
- Hematology; AO Città della Salute e della Scienza; Torino Italy
| | - D. Dessi
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - L. Melis
- Nuclear Medicine; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - G. Gaidano
- Hematology; AOU Maggiore della Carità di Novara; Novara Italy
| | - A. Chiti
- Nuclear Medicine; Humanitas Clinical and Research Hospital-IRCCS - Humanitas University; Rozzano Milano Italy
| | - M. Deidda
- Radiotherapy; Ospedale Oncologico Armando Businco; Cagliari Italy
| | - A. Santoro
- Medical Oncology and Hematology; Humanitas Clinical and Research Hospital-IRCCS-Humanitas University; Rozzano Milano Italy
| | - G. Ciccone
- Epidemiologia Clinica e Valutativa; AOU Città della Salute e della Scienza e CPO; Torino Italy
| | - S. Chauvie
- Medical Physics; Santa Croce e Carle Hospital; Cuneo Italy
| | - M. Cabras
- Hematology; Ospedale Oncologico Armando Businco; Cagliari Italy
| |
Collapse
|
23
|
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter M, Herling C, De Paoli L, Delgado J, Gentile M, Doubek M, Mauro F, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Moia R, Gerber B, Zucca E, Ghielmini M, Cavalli F, Stüssi G, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Wierda W, Montserrat E, Gaidano G, Hallek M, Rossi D. INTERNATIONAL PROGNOSTIC SCORE FOR EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (IPS-A). Hematol Oncol 2019. [DOI: 10.1002/hon.51_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Condoluci
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L. Terzi di Bergamo
- Experimental Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - P. Langerbeins
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - M. Hoechstetter
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - C. Herling
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - L. De Paoli
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - J. Delgado
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - M. Gentile
- Hematology; Azienda Ospedaliera (AO) of Cosenza; Cosenza Italy
| | - M. Doubek
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F.R. Mauro
- Hematology; Sapienza University; Rome Italy
| | - G. Chiodin
- Hematology; Southampton University; Southampton United Kingdom
| | - M. Mattsson
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - J. Bahlo
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - G. Cutrona
- Hematology; IRCCS Ospedale Policlinico San Martino; Genoa Italy
| | - J. Kotaskova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - C. Deambrogi
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - R. Moia
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - B. Gerber
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - E. Zucca
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Ghielmini
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Stüssi
- Onco-hematology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Neri
- Hematology; University of Milan; Milan Italy
| | | | - R. Rosenquist
- Immunology; Genetics and Pathology, Uppsala University; Uppsala Sweden
| | - F. Forconi
- Hematology; Southampton University; Southampton United Kingdom
| | - R. Foà
- Hematology; Sapienza University; Rome Italy
| | - S. Pospisilova
- Hematology and Oncology; University Hospital of Brno; Brno Czech Republic
| | - F. Morabito
- Hematology; Augusta Victoria Hospital; Jerusalem Israel
| | - W.G. Wierda
- MD Anderson Cancer Center; University of Texas; Houston United States
| | - E. Montserrat
- Hematology; Hospital Clínic de Barcelona; Barcelona Spain
| | - G. Gaidano
- Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Hallek
- University of Cologne; Center of Integrated Oncology Cologne-Bonn, German CLL Study Group; Köln Germany
| | - D. Rossi
- Experimental Hematology; Institute of Oncology Research; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
24
|
Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta-Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson P, Zucca E. EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT. Hematol Oncol 2019. [DOI: 10.1002/hon.136_2629] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Conconi
- Division of Hematology; Ospedale degli Infermi; Ponderano Italy
| | - C. Thieblemont
- Hemato-Oncology Department; Saint Louis Hospital; Paris France
| | - L. Cascione
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Torri
- Clinical Research Methodology Laboratory; IRCCS-Mario Negri Institute; Milan Italy
| | - B. Kiesewetter
- Division of Oncology; Department of Internal Medicine I, Medical University of Vienna; Vienna Austria
| | - G. Margiotta-Casaluci
- Division of Hematology, Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Gaidano
- Division of Hematology, Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - M. Raderer
- Division of Oncology; Department of Internal Medicine I, Medical University of Vienna; Vienna Austria
| | - F. Cavalli
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | | | - P.W. Johnson
- Cancer Research UK Center; Southampton General Hospital; Southampton United Kingdom
| | - E. Zucca
- Division of Medical Oncology; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
25
|
Bruscaggin A, Mollejo M, Tapia G, Gomes da Silva M, Novak U, Dietrich S, Ponzoni M, Rambaldi A, Corradini P, Vitolo U, Merli M, Tzankov A, Cogliatti S, Montalban C, Marasca R, de Leval L, Visco C, Baptista M, Tousseyn T, Facchetti F, Paulli M, Mazzucchelli L, Bea S, Oscier D, Zinzani P, Bhagat G, Inghirami G, Gaidano G, Traverse-Glehen A, Thieblemont C, Piris M, Cavalli F, Arcaini L, Zucca E, Rossi D. MULTI-OMICS LANDSCAPE OF SPLENIC MARGINAL ZONE LYMPHOMA (SMZL) - INTERIM ANALYSIS OF IELSG46 STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.138_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
26
|
Ricardi U, Levis M, Evangelista A, Gioia D, Rigacci L, Botto B, Simontacchi G, Franzone P, Rossi G, Buglione M, Pavone V, Bonfichi M, Rusconi C, Freilone R, Pulsoni A, De Sanctis V, Gaidano G, Stelitano C, Tani M, Castagnoli A, Ciccone G, Zaja F, Santoro A, Zinzani P. OC-0502 Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)30922-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Affiliation(s)
- A. Carbone
- Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano
| | - A. Gloghini
- Division of Pathology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano
| | - G. Gaidano
- Division of Internal Medicine, Department of Medical Sciences, Amedeo Avogadro University of Eastern Piedmont, Novara - Italy
| |
Collapse
|
28
|
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 2018; 29:525. [PMID: 28368466 DOI: 10.1093/annonc/mdx061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Toffoli G, Rossi D, Gaidano G, Cecchin E, Boiocchi M, Carbone A. Methylenetetrahydrofolate Reductase Genotype in Diffuse Large B-Cell Lymphomas with and without Hypermethylation of the DNA Repair Gene O6-Methylguanine DNA Methyltransferase. Int J Biol Markers 2018; 18:218-21. [PMID: 14535593 DOI: 10.1177/172460080301800310] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms have been suggested to affect susceptibility to malignant lymphoma, possibly by altering DNA methylation. The DNA repair gene O6-methylguanine DNA methyltransferase (MGMT) is transcriptionally silenced by promoter hypermethylation in diffuse large B-cell lymphomas (DLBCL). We analyzed the MTHFR677 and MTHFR1298 genotypes in 111 DLBCL patients and 465 controls. No significant difference in the frequency of MTHFR polymorphisms between patients and controls and no significant association between MTHFR677 or MTHFR1298 genotypes and methylation of MGMT promoter were observed. These results indicate that MTHFR variants are not related to DLBCL development and MGMT hypermethylation.
Collapse
Affiliation(s)
- G Toffoli
- Unit of Experimental and Clinical Pharmacology, CRO National Cancer Institute, Aviano (PN), Italy.
| | | | | | | | | | | |
Collapse
|
30
|
Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D’Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Leukemia 2017; 32:654-662. [DOI: 10.1038/leu.2017.296] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 08/23/2017] [Accepted: 09/08/2017] [Indexed: 12/16/2022]
|
31
|
Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 2017; 32:543-546. [PMID: 28924243 DOI: 10.1038/leu.2017.292] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- I Del Giudice
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - G M Rigolin
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - S Raponi
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - L Cafforio
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - C Ilari
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - J Wang
- Divisions of Life Science and Biomedical Engineering, Hong Kong University of Science and Technology, Hong Kong, China
| | - M Bordyuh
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Marinelli
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Nanni
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Filetti
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - A Bardi
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Tammiso
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Volta
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - M Negrini
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Saccenti
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F R Mauro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - D Rossi
- Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Cuneo
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - R Foà
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| |
Collapse
|
32
|
Ferrero S, Rossi D, Bruscaggin A, Evangelista A, Di Rocco A, Spina V, Stefoni V, Ghione P, Barbero D, Monitillo L, Gomes Da Silva M, Santoro A, Molinari A, Ferreri A, Piccin A, Cortelazzo S, Ladetto M, Gaidano G. KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_83] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Molecular Biotechnologies and Health Sciences - Hematology Division; Università di Torino; Torino Italy
| | - D. Rossi
- Hematology, Oncology; Institute of Southern Switzerland and Institute of Oncology Research; Bellinzona Switzerland
| | - A. Bruscaggin
- Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - A. Evangelista
- Clinical Epidemiology; Città della Salute e della Scienza and CPO Piemonte; Torino Italy
| | - A. Di Rocco
- Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I; "Sapienza" University of Rome; Rome Italy
| | - V. Spina
- Hematology; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Stefoni
- University of Bologna; Institute of Hematology "L. e A. Seràgnoli; Bologna Italy
| | - P. Ghione
- Molecular Biotechnologies and Health Sciences - Hematology Division; Università di Torino; Torino Italy
| | - D. Barbero
- Molecular Biotechnologies and Health Sciences - Hematology Division; Università di Torino; Torino Italy
| | - L. Monitillo
- Molecular Biotechnologies and Health Sciences - Hematology Division; Università di Torino; Torino Italy
| | - M. Gomes Da Silva
- Department of Hematology; Instituto Português de Oncologia de Lisboa; Lisbona Portugal
| | - A. Santoro
- Humanitas Clinical and Research Center; Humanitas Cancer Center; Rozzano Italy
| | - A. Molinari
- Hematology; Ospedale degli Infermi; Rimini Italy
| | - A. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Haematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - A. Piccin
- Department of Hematology; Ospedale Generale; Bolzano Italy
| | | | - M. Ladetto
- Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, SC Ematologia; Alessandria Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont, Division of Hematology; Novara Italy
| |
Collapse
|
33
|
Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi F, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M. NOTCH1
MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY a MYC
-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_43] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- F. Pozzo
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - T. Bittolo
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - E. Vendramini
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - R. Bomben
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - P. Bulian
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - F.M. Rossi
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - A. Zucchetto
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - E. Tissino
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - M. Degan
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - G. D'Arena
- Onco-Hematology Department; IRCCS “Centro di Riferimento Oncologico della Basilicata”; Rionero in Vulture Italy
| | - F. Di Raimondo
- Division of Hematology; Ferrarotto Hospital; Catania Italy
| | - F. Zaja
- Clinica Ematologica, Centro Trapianti e Terapie Cellulari; Azienda Ospedaliera Universitaria S. Maria Misericordia; Udine Italy
| | - G. Pozzato
- Department of Internal Medicine and Hematology; Maggiore General Hospital; Trieste Italy
| | - D. Rossi
- Hematology; Institute of Oncology Research and Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - G. Gaidano
- Division of Hematology-Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Del Poeta
- Division of Hematology; S.Eugenio Hospital and University of Tor Vergata; Rome Italy
| | - V. Gattei
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| | - M. Dal Bo
- Clinical and Experimental Onco-Hematology Unit; Centro di Riferimento Oncologico, I.R.C.C.S; Aviano Italy
| |
Collapse
|
34
|
Chiappella A, Agostinelli C, Martelli M, Evangelista A, Fabbri M, Melle F, Motta G, Righi S, Novero D, Balzarotti M, Cabras M, Carella A, Gotti M, Pavone V, Tucci A, Ladetto M, Gaidano G, Vitolo U, Pileri S. BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2, AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Chiappella
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - C. Agostinelli
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M. Martelli
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - A. Evangelista
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M. Fabbri
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - F. Melle
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - G. Motta
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - S. Righi
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - D. Novero
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M. Balzarotti
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M.G. Cabras
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - A.M. Carella
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M. Gotti
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - V. Pavone
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - A. Tucci
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - M. Ladetto
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - G. Gaidano
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - U. Vitolo
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| | - S.A. Pileri
- AOU Città della Salute e della Scienza di Torino; On behalf of Fondazione Italiana Linfomi (FIL); Torino Italy
| |
Collapse
|
35
|
Luminari S, Marcheselli L, Manni M, Anastasia A, Vitolo U, Chiarenza A, Rigacci L, Angelucci E, Fama A, Pulsoni A, Rattotti S, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri A, Tarantino V, Bellei M, Federico M. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_91] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Luminari
- Hematology; Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Anastasia
- Department of Hematology, ASST-Spedali Civili di Brescia; Brescia Italy
| | - U. Vitolo
- Hematology Unit; Città della Salute e della Scienza University and Hospital; Torino Italy
| | - A. Chiarenza
- Division of Hematology, AOU "Policlinico-Vittorio Emanuele"; University of Catania; Catania Italy
| | - L. Rigacci
- Hematology; University of Florence; Florence Italy
| | - E. Angelucci
- U.O. Ematologia, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro; Genoa Italy
| | - A. Fama
- Hematology Department, Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - A. Pulsoni
- Department of Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - S. Rattotti
- Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - F. Angrilli
- Department of Hematology; Transfusion Medicine and Biotechnology, Spirito Santo Hospital; Pescara Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont, Division of Hematology; Novara Italy
| | - C. Stelitano
- Division of Hematology, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli; Reggio Calabria Italy
| | - G. Bertoldero
- U O di Oncologia ed Ematologia Oncologica, Ospedale di Mirano; Mirano Italy
| | - N. Cascavilla
- Division of Hematology; IRCCS “Casa Sollievo della Sofferenza” Hospital; San Giovanni Rotondo Italy
| | - F. Salvi
- Department Hematology, Ospedale SS Antonio e Biagio; Alessandria Italy
| | - A.J. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Haematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
36
|
Luminari S, Tarantino V, Anastasia A, Boccomini C, Chiarenza A, Rigacci L, Angelucci E, Ferrari A, Pulsoni A, Rattotti S, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri A, Vallisa D, Balzarotti M, Cox M, Freilone R, Marcheselli L, Dondi A, Manni M, Federico M. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. Luminari
- Hematology Unit; Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Anastasia
- Department of Hematology; ASST-Spedali Civili di Brescia; Brescia Italy
| | - C. Boccomini
- Hematology Unit; Città della Salute e della Scienza University and Hospital; Torino Italy
| | - A. Chiarenza
- Division of Hematology, AOU "Policlinico-Vittorio Emanuele"; University of Catania; Catania Italy
| | - L. Rigacci
- Hematology; University of Florence; Florence Italy
| | - E. Angelucci
- U.O. Ematologia; IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro; Genoa Italy
| | - A. Ferrari
- Hematology Unit, Arcispedale Santa Maria Nuova; IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - A. Pulsoni
- Department of Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - S. Rattotti
- Department of Hematology-Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - F. Angrilli
- Department of Hematology; Transfusion Medicine and Biotechnology, Spirito Santo Hospital; Pescara Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont., University of Eastern Piedmont, Division of Hematology; Novara Italy
| | - C. Stelitano
- Division of Hematology; Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli; Reggio Calabria Italy
| | - G. Bertoldero
- U O di Oncologia ed Ematologia Oncologica; Ospedale di Mirano; Mirano Italy
| | - N. Cascavilla
- Division of Hematology; IRCCS "Casa Sollievo della Sofferenza" Hospital; San Giovanni Rotondo Italy
| | - F. Salvi
- Department Hematology; Ospedale SS Antonio e Biagio; Alessandria Italy
| | - A.J. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Haematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - D. Vallisa
- Department of Hematology; Guglielmo da Saliceto Hospital; Piacenza Italy
| | - M. Balzarotti
- Hematology; IRCCS Humanitas Cancer Center; Rozzano, Milano Italy
| | - M.C. Cox
- Hematology Unit; Sant'andrea Hospital; Rome Italy
| | - R. Freilone
- Hematology Unit, Department of Medicine; ASLT04 Piedmont, Ivrea- Ciriè-Chivasso; Italy
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Dondi
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
37
|
Bruscaggin A, Spina V, Di Trani M, Martini M, Locatelli S, Cupelli E, Forestieri G, Condoluci A, Cuccaro A, Moccia A, Stathis A, Manzoni M, Deambrogi C, Diop F, Stüssi G, Cavalli F, Bertoni F, Zucca E, Larocca L, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_51] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Bruscaggin
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - V. Spina
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - M. Di Trani
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - M. Martini
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - S. Locatelli
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - E. Cupelli
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Forestieri
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - A. Condoluci
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Cuccaro
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - A. Moccia
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - A. Stathis
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - M. Manzoni
- Department of Oncology and Hemato-Oncology; University of Milano; Milan Italy
| | - C. Deambrogi
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - F. Diop
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - G. Stüssi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Cavalli
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - F. Bertoni
- IOR; Institute of Oncology Research; Bellinzona Switzerland
| | - E. Zucca
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| | - L.M. Larocca
- Division of Pathology and Histology; Catholic University of the Sacred Heart; Rome Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont; Novara Italy
| | - S. Hohaus
- Institute of Hematology; Catholic University of the Sacred Heart; Rome Italy
| | - C. Carlo-Stella
- Department of Oncology and Haematology; Humanitas Cancer Center, Humanitas Clinical and Research Center; Rozzano Italy
| | - D. Rossi
- IOSI; Oncology Institute of Southern Switzerland; Bellinzona Switzerland
| |
Collapse
|
38
|
Ghia P, Scarfò L, Coscia M, Sancetta R, Ferrario A, Tedeschi A, Farina L, Laurenti L, Orlandi E, Reda G, Motta M, Carlo Stella C, Massaia M, Quaresmini G, Rossini F, Ladetto M, Gaidano G, Rossi V, Montillo M. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY). Hematol Oncol 2017. [DOI: 10.1002/hon.2440_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- P. Ghia
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - L. Scarfò
- Strategic Program on CLL; IRCCS Ospedale San Raffaele; Milan Italy
| | - M. Coscia
- Division of Hematology, University of Torino; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - R. Sancetta
- U.O.C. Ematologia; Azienda ULSS 3 Serenissima; Mestre Italy
| | - A. Ferrario
- UOC Ematologia; Azienda Socio Sanitaria Territoriale dei Sette Laghi Ospedale di Circolo e Fondazione Macchi; Varese Italy
| | - A. Tedeschi
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| | - L. Farina
- Istituto Nazionale dei Tumori; Unità Trapianto di Midollo; Milan Italy
| | - L. Laurenti
- Policlinico A. Gemelli; Università Cattolica del Sacro Cuore; Rome Italy
| | - E. Orlandi
- S.C Ematologia; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - G. Reda
- UOC Oncoematologia; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Milan Italy
| | - M. Motta
- U.O. Ematologia; Spedali Civili di Brescia-Azienda Ospedaliera; Brescia Italy
| | - C. Carlo Stella
- Sezione di Ematologia; Cancer Center Humanitas; Rozzano Italy
| | - M. Massaia
- Struttura Complessa di Ematologia; Azienda Ospedaliera S. Croce e Carle di Cuneo; Cuneo
| | - G. Quaresmini
- Ematologia; Azienda Ospedaliera Papa Giovanni XXIII; Bergamo Italy
| | - F. Rossini
- Divisione di Ematologia e Trapianto di Midollo, Ospedale S. Gerardo; Universita' di Milano Bicocca; Monza Italy
| | - M. Ladetto
- Ematologia; Presidio Ospedaliero SS Antonio e Biagio; Alessandria Italy
| | - G. Gaidano
- Divisione di Ematologia; Università del Piemonte Orientale "Amedeo Avogadro"; Novara Italy
| | - V. Rossi
- Hematology & Transfusion Medicine; L. Sacco University Hospital & School of Medicine; Milan Italy
| | - M. Montillo
- Department of Haematology & Oncology Service of Haematology; Niguarda Cancer Center Niguarda Hospital; Milan Italy
| |
Collapse
|
39
|
Merli F, Luminari S, Salvi F, Cavallo F, Gini G, Musuraca G, Gaidano G, Cellini C, Merli M, Ferrari A, Molinari A, Liberati A, Conconi A, Matteucci P, Pozzi S, Musso M, Mammi C, Monaco F, Ferrero S, Tucci A. OBINUTUZUMAB-MINICHOP FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. A STUDY OF THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Merli
- Hematology; Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - S. Luminari
- Hematology; Arcispedale Santa Maria Nuova-IRCCS and University of Modena and Reggio Emilia; Reggio Emilia Italy
| | - F. Salvi
- Hematology Unit; Antonio e Biagio e Cesare Arrigo Hospital; Alessandria Italy
| | - F. Cavallo
- Division of Hematology; University of Torino; Torino Italy
| | - G. Gini
- Division of Hematology; Ospedali Riuniti; Ancona Italy
| | - G. Musuraca
- Hematology Unit; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS; Meldola (FC) Italy
| | - G. Gaidano
- Division of Hematology, Department of Translational Medicine; Amedeo Avogadro University of Eastern Piedmont; Novara Italy
| | - C. Cellini
- Hematology Unit; Santa Maria delle Croci Hospital; Ravenna Italy
| | - M. Merli
- Division of Hematology; University Hospital “Ospedale di Circolo e Fondazione Macchi-ASST Sette Laghi”; Varese Italy
| | - A. Ferrari
- Hematology; Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - A. Molinari
- Hematology; Ospedale degli Infermi; Rimini (FC) Italy
| | - A.M. Liberati
- Department of Oncohematology; S.Maria Hospital; Terni Italy
| | - A. Conconi
- Unit of Hematology; Department of Internal Medicine, Ospedale degli Infermi; Ponderano (BI) Italy
| | - P. Matteucci
- Haematology and Bone Marrow Transplantation Unit; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy
| | - S. Pozzi
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Musso
- Division of Hematology; La Maddalena Hospital; Palermo Italy
| | - C. Mammi
- GRADE onlus; Gruppo Amici dell'Ematologia; Reggio Emilia Italy
| | - F. Monaco
- Hematology Unit; Antonio e Biagio e Cesare Arrigo Hospital; Alessandria Italy
| | - S. Ferrero
- Division of Hematology; University of Torino; Torino Italy
| | - A. Tucci
- Hematology; Spedali Civili Hospital; Brescia Italy
| |
Collapse
|
40
|
Rigacci L, Puccini B, Zinzani P, Kovalchuk S, Broccoli A, Evangelista A, Gioia D, Mannelli L, Castagnoli A, Santoro A, Bonfichi M, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Borsatti E, Levis A. CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_19] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | | | - P. Zinzani
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - A. Broccoli
- Hematology; Ospedale Sant'Orsola Malpighi; Bologna Italy
| | | | - D. Gioia
- Hematology; Ospedale Alessandria; Alessandria Italy
| | | | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Milan Italy
| | | | - G. Rossi
- Hematology; Ospedale Brescia; Brescia Italy
| | | | - F. Zaja
- Hematology; Ospedale Udine; Udine Italy
| | - U. Vitolo
- Hematology; AOU Città della Salute; Torino Italy
| | - V. Pavone
- Hematology; Ospedale Tricase; Tricase Italy
| | - A. Pulsoni
- Hematology; Università la Sapienza; Rome Italy
| | - G. Gaidano
- Hematology; Università Novara; Novara Italy
| | - C. Stelitano
- Hematology; Ospedale Reggio Calabria; Reggio Calabria Italy
| | - F. Salvi
- Hematology; Ospedale Alessandria; Alessandria Italy
| | - C. Rusconi
- Hematology; Ospedale Niguarda Ca' Grande; Milan Italy
| | - M. Tani
- Hematology; Ospedale Ravenna; Ravenna Italy
| | | | | | - A. Levis
- Hematology; Ospedale Alessandria; Alessandria Italy
| |
Collapse
|
41
|
Kantarjian H, Fenaux P, Sekeres M, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Jedrzejczak W, Carpenter N, Mehta B, Franklin J, Giagounidis A. Romiplostim in Low/INT-1-Risk MDS Results in Reduced Bleeding without Impacting Leukemic Progression: Final Results from a Randomized, Double-Blind, Placebo-Controlled Study. Leuk Res 2017. [DOI: 10.1016/s0145-2126(17)30136-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
42
|
Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M. NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components. Leukemia 2017; 31:2407-2415. [PMID: 28321119 DOI: 10.1038/leu.2017.90] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Revised: 03/13/2017] [Accepted: 03/16/2017] [Indexed: 12/24/2022]
Abstract
In chronic lymphocytic leukemia (CLL), the mechanisms controlling cell growth and proliferation in the presence of NOTCH1 mutations remain largely unexplored. By performing a gene expression profile of NOTCH1-mutated (NOTCH1-mut) versus NOTCH1 wild-type CLL, we identified a gene signature of NOTCH1-mut CLL characterized by the upregulation of genes related to ribosome biogenesis, such as nucleophosmin 1 (NPM1) and ribosomal proteins (RNPs). Activation of NOTCH1 signaling by ethylenediaminetetraacetic acid or by coculture with JAGGED1-expressing stromal cells increased NPM1 expression, and inhibition of NOTCH1 signaling by either NOTCH1-specific small interfering RNA (siRNA) or γ-secretase inhibitor reduced NPM1 expression. Bioinformatic analyses and in vitro activation/inhibition of NOTCH1 signaling suggested a role of MYC as a mediator of NOTCH1 effects over NPM1 and RNP expression in NOTCH1-mut CLL. Chromatin immunoprecipitation experiments performed on NOTCH1 intracellular domain (NICD)-transfected CLL-like cells showed the direct binding of NOTCH1 to the MYC promoter, and transfection with MYC-specific siRNA reduced NPM1 expression. In turn, NPM1 determined a proliferation advantage of CLL-like cells, as demonstrated by NPM1-specific siRNA transfection. In conclusion, NOTCH1 mutations in CLL are associated with the overexpression of MYC and MYC-related genes involved in protein biosynthesis including NPM1, which are allegedly responsible for cell growth and/or proliferation advantages of NOTCH1-mut CLL.
Collapse
Affiliation(s)
- F Pozzo
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - T Bittolo
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - E Vendramini
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - R Bomben
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - P Bulian
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - F M Rossi
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - A Zucchetto
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - E Tissino
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - M Degan
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - G D'Arena
- Department of Onco-Hematology, IRCCS 'Centro di Riferimento Oncologico della Basilicata', Rionero in Vulture, Italy
| | - F Di Raimondo
- Division of Hematology, Ferrarotto Hospital, Catania, Italy
| | - F Zaja
- Clinica Ematologica, Centro Trapianti e Terapie Cellulari 'Carlo Melzi' DISM, Azienda Ospedaliera Universitaria S Maria Misericordia, Udine, Italy
| | - G Pozzato
- Department of Internal Medicine and Hematology, Maggiore General Hospital, University of Trieste, Trieste, Italy
| | - D Rossi
- Hematology, Institute of Oncology Research and Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
| | - G Gaidano
- Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy
| | - G Del Poeta
- Division of Hematology, S Eugenio Hospital and University of Tor Vergata, Rome, Italy
| | - V Gattei
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| | - M Dal Bo
- Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, IRCCS, Aviano, Italy
| |
Collapse
|
43
|
Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hájek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia 2017; 31:115-122. [PMID: 27491641 PMCID: PMC5220137 DOI: 10.1038/leu.2016.186] [Citation(s) in RCA: 52] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 06/22/2016] [Indexed: 01/15/2023]
Abstract
The randomized phase 3 ENDEAVOR study (N=929) compared carfilzomib and dexamethasone (Kd) with bortezomib and dexamethasone (Vd) in relapsed multiple myeloma (RMM). We performed a subgroup analysis from ENDEAVOR in patients categorized by number of prior lines of therapy or by prior treatment. Median progression-free survival (PFS) for patients with one prior line was 22.2 months for Kd vs 10.1 months for Vd, and median PFS for patients with ⩾2 prior lines was 14.9 months for Kd vs 8.4 months for Vd. For patients with prior bortezomib exposure, the median PFS was 15.6 months for Kd vs 8.1 months for Vd, and for patients with prior lenalidomide exposure the median PFS was 12.9 months for Kd vs 7.3 months for Vd. Overall response rates (Kd vs Vd) were 81.9 vs 65.5% (one prior line), 72.0 vs 59.7% (⩾2 prior lines), 71.2 vs 60.3% (prior bortezomib) and 70.1 vs 59.3% (prior lenalidomide). The safety profile in the prior lines subgroups was qualitatively similar to that in the broader ENDEAVOR population. In RMM, outcomes are improved when receiving treatment with carfilzomib compared with bortezomib, regardless of the number of prior therapy lines or prior exposure to bortezomib or lenalidomide.
Collapse
Affiliation(s)
- P Moreau
- University of Nantes, Nantes, France
| | - D Joshua
- Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | - W-J Chng
- National University Cancer Institute, National University Health System; Cancer Science Institute of Singapore, National University of Singapore, Singapore
| | | | | | - R Hájek
- University Hospital Ostrava, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
| | - T Facon
- CHRU Lille Hôpital Claude Huriez, Lille, France
| | - H Ludwig
- Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria
| | - L Pour
- University Hospital Brno, Brno, Czech Republic
| | - R Niesvizky
- Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY, USA
| | - A Oriol
- Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
| | - L Rosiñol
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - A Suvorov
- Hematological Department, First Republican Clinical Hospital of Udmurtia, Izhevsk, Russia
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - T Pika
- Department of Hematooncology, University Hospital Olomouc, Olomouc, Czech Republic
| | - K Weisel
- Universitätsklinikum Tübingen, Tübingen, Germany
| | - V Goranova-Marinova
- University Multiprofile Hospital for Active Treatment ‘Sv. Georgi' and Medical University, Plovdiv, Bulgaria
| | - H H Gillenwater
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
| | - N Mohamed
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
| | - S Aggarwal
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
| | - S Feng
- Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
| | - M A Dimopoulos
- National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
44
|
Arruga F, Gizdic B, Bologna C, Cignetto S, Buonincontri R, Serra S, Vaisitti T, Gizzi K, Vitale N, Garaffo G, Mereu E, Diop F, Neri F, Incarnato D, Coscia M, Allan J, Piva R, Oliviero S, Furman RR, Rossi D, Gaidano G, Deaglio S. Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Leukemia 2016; 31:1882-1893. [DOI: 10.1038/leu.2016.383] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 11/03/2016] [Accepted: 11/28/2016] [Indexed: 12/26/2022]
|
45
|
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F. EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia 2016; 31:1547-1554. [PMID: 27890934 DOI: 10.1038/leu.2016.359] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Revised: 11/04/2016] [Accepted: 11/09/2016] [Indexed: 12/11/2022]
Abstract
Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2-mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort. A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations. In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome.
Collapse
Affiliation(s)
- E Young
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - D Noerenberg
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
| | - L Mansouri
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - V Ljungström
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - M Frick
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
| | - L-A Sutton
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - S J Blakemore
- Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | - J Galan-Sousa
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
| | - K Plevova
- Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - P Baliakas
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.,Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
| | - R Clifford
- Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK
| | - D Roos-Weil
- INSERM, U1170, Institut Gustave Roussy, Villejuif, France
| | - V Navrkalova
- Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - B Dörken
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
| | - C A Schmitt
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany
| | - K E Smedby
- Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden
| | - G Juliusson
- Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden
| | - B Giacopelli
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - J S Blachly
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - C Belessi
- Hematology Department, General Hospital of Nikea, Piraeus, Greece
| | - P Panagiotidis
- First Department of Propaedeutic Medicine, School of Medicine, University of Athens, Athens, Greece
| | - N Chiorazzi
- Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA
| | - F Davi
- Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France
| | - A W Langerak
- Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - D Oscier
- Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK
| | - A Schuh
- Oxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - P Ghia
- Università Vita-Salute San Raffaele, Milan, Italy.,Division of Experimental Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy
| | - W Xu
- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
| | - L Fan
- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
| | - O A Bernard
- INSERM, U1170, Institut Gustave Roussy, Villejuif, France
| | - F Nguyen-Khac
- Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France
| | - L Rassenti
- Division of Hematology/Oncology, Department of Medicine, University of California at San Diego/Moores Cancer Center, La Jolla, CA, USA
| | - J Li
- Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China
| | - T J Kipps
- Division of Hematology/Oncology, Department of Medicine, University of California at San Diego/Moores Cancer Center, La Jolla, CA, USA
| | - K Stamatopoulos
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.,Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece
| | - S Pospisilova
- Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic
| | - T Zenz
- Department of Molecular Therapy in Haematology and Oncology (G250) and Department of Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.,German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany
| | - C C Oakes
- Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
| | - J C Strefford
- Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | - R Rosenquist
- Department of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden
| | - F Damm
- Department of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.,German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germany.,Berlin Institute of Health (BIH), Berlin, Germany
| |
Collapse
|
46
|
De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larrán A, Iurlo A, Randi ML, Pieri L, Rossi E, Guglielmelli P, Betti S, Elli E, Finazzi MC, Finazzi G, Zetterberg E, Vianelli N, Gaidano G, Nichele I, Cattaneo D, Palova M, Ellis MH, Cacciola E, Tieghi A, Hernandez-Boluda JC, Pungolino E, Specchia G, Rapezzi D, Forcina A, Musolino C, Carobbio A, Griesshammer M, Barbui T. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J 2016; 6:e493. [PMID: 27813534 PMCID: PMC5148051 DOI: 10.1038/bcj.2016.103] [Citation(s) in RCA: 70] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Accepted: 09/16/2016] [Indexed: 12/13/2022] Open
Abstract
We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.
Collapse
Affiliation(s)
- V De Stefano
- Institute of Hematology, Catholic University, Roma, Italy
| | - A M Vannucchi
- Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy
| | - M Ruggeri
- Ospedale San Bortolo, Vicenza, Italy
| | | | - A Alvarez-Larrán
- Department of Hematology, Hospital del Mar-IMIM, Barcelona, Spain
| | - A Iurlo
- Oncohematology Division, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - M L Randi
- Clinica Medica 1, Università di Padova, Padova, Italy
| | - L Pieri
- Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy
| | - E Rossi
- Institute of Hematology, Catholic University, Roma, Italy
| | - P Guglielmelli
- Center for Research and Innovation of Myeloproliferative Neoplasms, A.O.U. Careggi, University of Florence, Florence, Italy
| | - S Betti
- Institute of Hematology, Catholic University, Roma, Italy
| | - E Elli
- Divisione di Ematologia, Ospedale San Gerardo, ASST Monza, Italy
| | - M C Finazzi
- Hematology Division, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - G Finazzi
- Hematology Division, ASST Papa Giovanni XXIII, Bergamo, Italy
| | | | - N Vianelli
- Institute of Hematology and Medical Oncology, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Gaidano
- Department of Translational Medicine, Università del Piemonte Orientale, Vercelli, Italy
| | - I Nichele
- Ospedale San Bortolo, Vicenza, Italy
| | - D Cattaneo
- Oncohematology Division, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
| | - M Palova
- University Hospital of Olomouc, Olomouc, Czech Republic
| | - M H Ellis
- Department of Hematology, Institute Meir Medical Center, Kfar Saba, Israel
| | - E Cacciola
- Haemostasis Unit, Department of Medical, Surgical and Advanced Technologies Sciences 'G.F. Ingrassia', University of Catania, Catania, Italy
| | - A Tieghi
- Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | | | - E Pungolino
- A.O. Ospedale Niguarda Ca' Granda, Milano, Italy
| | - G Specchia
- A.O. Universitaria, Policlinico di Bari, Italy
| | - D Rapezzi
- A.O. Santa Croce e Carle, Cuneo, Italy
| | - A Forcina
- IRCCS Ospedale San Raffaele, Milano, Italy
| | | | - A Carobbio
- FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - M Griesshammer
- Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - T Barbui
- FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
47
|
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, Luminari S, Pott C, Zamò A, Zucca E. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 2016; 27:2149-2160. [PMID: 27701070 DOI: 10.1093/annonc/mdw419] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2016] [Revised: 08/11/2016] [Accepted: 08/23/2016] [Indexed: 01/02/2023] Open
Abstract
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of 25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic factors suitable for clinical use and (iii) the 'ultra-high-risk' group. Before the conference, the expert panel was divided into three working groups; each group focused on one of these areas in order to address four clinically relevant questions relating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, each working group developed recommendations to address each of the four questions assigned to their group. These recommendations were then presented to the entire panel and a consensus was reached. This manuscript presents recommendations dedicated to the second area of interest, i.e. prognostic factors suitable for clinical use. The four topics [i.e. interim positron emission tomography (PET), TP53 mutations, cell of origin (COO) and minimal residual disease (MRD)] were primarily chosen because of the bulk of available data together with the lack of clear guidance regarding their use in clinical practice and within clinical trials. Results, including a summary of evidence supporting each recommendation, are detailed in this manuscript. The panel acknowledged that detection of TP53 inactivation by deletion or mutation in CLL should be implemented in clinical practice (level of evidence I, strength of recommendation A). Due to their potentially high prognostic value, at least in some lymphoma entities, implementation of interim PET, COO and MRD was highly recommended in the context of clinical trials. All expert panel members approved this final article.
Collapse
Affiliation(s)
- M Ladetto
- Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| | - C Buske
- Comprehensive Cancer Center Ulm and Department of Internal Medicine III, Institute of Experimental Cancer Research, University Hospital, Ulm, Germany
| | - M Hutchings
- Department of Hematology, Rigshospitalet, Copenhagen, Denmark
| | - M Dreyling
- Medizinische Klinik III, Klinikum der Universität München/LMU, Munich, Germany
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - S Le Gouill
- Clinical Hematology, Centre Hospitalo-Universitaire de Nantes, UMR892 Team 10, CIC Nantes, France
| | - S Luminari
- Hematology, Arcispedale S. Maria Nuova, IRCCS Reggio Emilia.,Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - C Pott
- Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A Zamò
- Department of Diagnostics and Public Health, University of Verona, Verona, Italy
| | - E Zucca
- Lymphoma Unit, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
| | | |
Collapse
|
48
|
Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, Moccia A, Rancoita P, Gribben J, Cavalli F, Gaidano G, Lister T, Montserrat E, Ghielmini M, Zucca E. Life expectancy of young adults with follicular lymphoma. Ann Oncol 2015; 26:2317-22. [DOI: 10.1093/annonc/mdv376] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2015] [Accepted: 09/07/2015] [Indexed: 11/13/2022] Open
|
49
|
Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia A, Bertoni F, Ramponi A, Mazzucchelli L, Cavalli F, Gaidano G, Zucca E. Histologic transformation in marginal zone lymphomas. Ann Oncol 2015; 26:2329-35. [DOI: 10.1093/annonc/mdv368] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Accepted: 08/26/2015] [Indexed: 01/14/2023] Open
|
50
|
Gobba S, Moccia A, Conconi A, Diem S, Cascione L, Aprile von Hohenstaufen K, Gulden-Sala W, Stathis A, Hitz F, Gaidano G, Zucca E, Pinotti G. Survival and prognostic factors in very elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of 281 patients over 80 years. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|